- Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications
- The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy
- DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification
- Shotgun proteomics of archival triple-negative breast cancer samples
- Gene signatures in breast cancer: current and future uses
- MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients
- PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics
- High‐Throughput Phosphoproteomics from Formalin‐Fixed, Paraffin‐Embedded Tissues
- The present and future of gene profiling in breast cancer
- Gene profiling in breast cancer: time to move forward
- Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches
- An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer
- Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues
- MALDI profiling of human lung cancer subtypes
- Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer
- Pathogenic validation of unique germline intronic variants of RB1 in retinoblastoma patients using minigenes
